<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338764</url>
  </required_header>
  <id_info>
    <org_study_id>SM-A-06</org_study_id>
    <nct_id>NCT03338764</nct_id>
  </id_info>
  <brief_title>An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequential Medicine Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequential Medicine Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and pattern of use of the combination&#xD;
      drug product SM-1 in adults who sometimes have difficulty in falling asleep or staying&#xD;
      asleep, but who do not have chronic insomnia. Participants will receive SM-1 or placebo to&#xD;
      take at home as needed over the course of 3 months treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the efficacy, safety, tolerability and pattern of use&#xD;
      of SM-1 in adults who sometimes have difficulty in falling asleep or staying asleep, but who&#xD;
      do not have chronic insomnia. SM-1 is a combination drug product containing diphenhydramine,&#xD;
      zolpidem and lorazepam. The study is a parallel group design; participants will receive&#xD;
      either SM-1 or placebo to take at home as needed over the course of 3 months treatment&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Total Sleep Time</measure>
    <time_frame>7 nights</time_frame>
    <description>Total time spent sleeping each night as reported by the subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pattern of use</measure>
    <time_frame>3 months</time_frame>
    <description>Subject reported total number of uses and consecutive nights of use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Adverse Events</measure>
    <time_frame>Through study completion, 17 weeks</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Residual Effects</measure>
    <time_frame>Through study completion, 17 weeks</time_frame>
    <description>Subject reported answer to the Question, &quot;How alert or sleepy do you feel this morning?&quot; Subjects will rate their alertness on a scale from 0 to 5, with 0 being extremely sleepy and 5 being extremely alert</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Rebound Insomnia</measure>
    <time_frame>Through study completion, 17 weeks</time_frame>
    <description>Total time spent sleeping each night as reported by the subject on night after taking drug or night after not taking drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Transient Insomnia</condition>
  <arm_group>
    <arm_group_label>Experimental (SM-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-1</intervention_name>
    <description>SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep</description>
    <arm_group_label>Experimental (SM-1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Experienced at least 1 prior episode of transient insomnia meeting all of the&#xD;
             following criteria: difficulty falling asleep or staying asleep; next day impairment&#xD;
             or distress associated with the disturbed sleep; frequency of 1 to 7 nights per week;&#xD;
             duration of less than 1 month or more than 1 month of intermittent episodes.&#xD;
&#xD;
          -  Routinely spends 6.5 - 9.5 hours in bed each night, with bed time varying no more than&#xD;
             2 hours over a week.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 19 and 32 kg/m2.&#xD;
&#xD;
          -  Good general health, as determined by a thorough medical, sleep and psychiatric&#xD;
             history review, brief physical examination including vital sign measurements, and an&#xD;
             assessment of screening laboratory test results.&#xD;
&#xD;
          -  Agrees, for the duration of the study, to take only study drug to address difficulty&#xD;
             falling asleep or staying asleep, and to not drink alcohol within 2 hours of expected&#xD;
             bedtime.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, breast-feeding, or planning a pregnancy during the study&#xD;
             period.&#xD;
&#xD;
          -  Clinically significant medical disorder or currently unstable medical condition that,&#xD;
             in the opinion of the investigator, would confound the results of the study.&#xD;
&#xD;
          -  Abnormal laboratory value at screening, judged clinically significant by the&#xD;
             investigator.&#xD;
&#xD;
          -  History or current evidence of severe hepatic (liver) impairment.&#xD;
&#xD;
          -  Clinically significant psychiatric illness, or the history or presence of a major&#xD;
             psychiatric illness in the past year.&#xD;
&#xD;
          -  Has a significant risk (in the opinion of the investigator) for suicidal behavior&#xD;
             during the course of participation in the study or a) At screening: the subject scores&#xD;
             &quot;yes&quot; on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to&#xD;
             a 6-month period prior to screening; or b) At screening: the subject has had one or&#xD;
             more suicidal attempts within a 2-year period prior to screening; or c) At the&#xD;
             baseline visit: the subject scores &quot;yes&quot; on items 4 or 5 in the Suicidal Ideation&#xD;
             section of the C-SSRS with reference to screening; or d) The subject is considered to&#xD;
             be an imminent danger to self or others.&#xD;
&#xD;
          -  Has a history of chronic insomnia or other sleep disorders, such as sleep apnea,&#xD;
             narcolepsy, parasomnia, restless leg syndrome, or circadian rhythm disorder.&#xD;
&#xD;
          -  Has used medications to aid sleep on most nights during the past 2 months.&#xD;
&#xD;
          -  Has a history of night work or shift work within the month prior to screening or a&#xD;
             need to participate in night work or shift work during the study.&#xD;
&#xD;
          -  Has a history of alcohol or substance use disorder within the year prior to screening,&#xD;
             or current evidence of alcohol or substance use disorder as defined by the Diagnostic&#xD;
             and Statistical Manual of the American Psychiatric Association, 5th Edition.&#xD;
&#xD;
          -  Self-report of a usual consumption of more than 14 units of alcohol per week: 1 unit&#xD;
             of alcohol is equivalent to 12 ounces of beer, 4 ounces of wine, or 1 ounce of liquor.&#xD;
&#xD;
          -  Has a history of routinely smoking during sleep period.&#xD;
&#xD;
          -  Has discontinued smoking or participated in a smoking cessation program within 28 days&#xD;
             of screening, or plans to discontinue smoking during the study.&#xD;
&#xD;
          -  Has used within 2 weeks or 5 half-lives (whichever is longer) prior to screening of&#xD;
             any medication that affects sleep-wake function.&#xD;
&#xD;
          -  Has a positive urine drug screen at the screening visit.&#xD;
&#xD;
          -  Has a history of allergy or known sensitivity, hypersensitivity, or adverse reaction&#xD;
             to diphenhydramine, zolpidem, lorazepam, or related compounds.&#xD;
&#xD;
          -  Has had treatment with any other investigational drug within 28 days or 5 half-lives&#xD;
             (whichever is longer) prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Dahl</last_name>
    <phone>+1 617-818-2735</phone>
    <email>tadahl@outlook.com</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transient insomnia</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Sleep initiation and maintenance disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

